As the domain of molecular biomarkers and companion diagnostics in oncology expands, having a comprehensive understanding of the variants within cancer types that may predict sensitivity or resistance to an investigational targeted therapy continues to underscore the development of effective drugs. Guiding the right population to the right drug or clinical trial based on biomarker profiles is mutually beneficial to current patients, drug developers, and future patients.

In this webinar, a panel of industry leaders will explore:

  • How molecular biomarkers are driving companion diagnostics
  • Implications for expanding molecular biomarker profiles in the future
  • What may be on the horizon for regulatory/reimbursement of companion diagnostic panels
  • How genomic analyses may support clinical trial and companion diagnostic design in this evolving world